Dr. John A. Kessler's lab at Northwestern University focuses on understanding the role of specific proteins in brain health, particularly in the context of neurodegenerative diseases like Alzheimer's and frontotemporal dementia. His research examines how aging affects brain function and explores potential gene therapies to improve cognitive outcomes by targeting certain molecular pathways. The lab seeks to develop treatments that could ultimately help in preventing or slowing the progression of these debilitating conditions.

Dr. Habibeh Khoshbouei leads a research lab at the University of Florida focused on understanding the relationship between vagus nerve stimulation and dopamine regulation in the brain. Their work aims to address the challenges of methamphetamine addiction by exploring how stimulating the vagus nerve can influence dopamine levels and reduce the drug's effects. The lab employs various advanced techniques to study how these physiological responses can potentially lead to new treatment options for addiction.

Dr. Roozbeh Kiani's lab at New York University focuses on understanding and controlling neural activity in the brain to develop new treatments for disorders like Parkinson's disease and depression. They employ advanced techniques to monitor and influence brain circuits during decision-making and movement, bridging the gap between cognitive functions and motor actions. By using data-driven methods and targeted stimulation, their research aims to advance therapies and brain-computer interface technologies, providing solutions for neurological and psychiatric conditions.

Dr. Peter H. King’s lab focuses on understanding and potentially treating inflammation caused by ischemic strokes, which are a significant cause of death and disability. The team investigates a molecule called HuR that plays a role in promoting inflammation in the brain after a stroke. By inhibiting HuR, they aim to reduce inflammation and enhance neuroprotection to improve recovery outcomes for stroke patients, ultimately contributing to better management of strokes and related neurological diseases.

Dr. Evangelos Kiskinis's lab at Northwestern University focuses on understanding the biological mechanisms behind Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The lab utilizes advanced techniques like stem cell models and genetic analysis to explore how mutations in specific genes affect motor neuron function and health. This research aims to improve models for studying these neurodegenerative diseases and identify potential treatments.

Dr. Pamela E. Knapp's lab focuses on the effects of abnormal Tau protein on brain health, specifically regarding cognitive dysfunction in individuals with HIV and opioid use disorder. The lab uses animal models to investigate how Tau (specifically its phosphorylated form, pTau) contributes to neurological impairments. The research aims to uncover if targeting pTau can improve cognitive outcomes for these populations by examining neuronal function and behavior over time.

Dr. Kristen Knutson's lab focuses on understanding the connection between sleep and Alzheimer's disease by studying how specific proteins in the blood are influenced by sleep patterns. The research aims to identify biomarkers that can predict cognitive performance and dementia risk, providing insights that could lead to better prevention strategies. Ultimately, their work seeks to connect sleep health with brain function, especially in older adults.

Dr. Minoree Kohwi's lab at Columbia University investigates how neural progenitors organize their genomes to generate diverse types of neurons during brain development. By studying the Drosophila fruit fly model, the lab explores the relationship between genome organization, gene expression, and neuronal identity, providing insights into fundamental processes of neurodevelopment that are critical for cognitive and motor functions.

Dr. Dennis Kolson's lab at the University of Pennsylvania focuses on understanding and preventing brain injury related to HIV infection. The lab investigates how combining existing HIV therapies with new neuroprotective agents may reduce neurological damage and improve cognitive function in patients. Their groundbreaking work uses Rhesus macaques to explore the potential of a drug called dimethyl fumarate to enhance brain recovery following early HIV infection.

Dr. Joel H. Kramer and his lab at UCSF focus on understanding small vessel cerebrovascular disease, particularly how it contributes to cognitive decline in older adults. They aim to identify reliable markers that can help detect and monitor this disease early on, improving how we diagnose and treat affected patients. By following a diverse group of older individuals showing signs of cerebrovascular issues, they are working to validate new neuroimaging and fluid-based biomarkers that could greatly enhance clinical trials and patient care.

Dr. Chia-Yi Kuan's lab focuses on understanding the causes and potential treatments for diseases that affect the brain, particularly Alzheimer's disease and neonatal brain injuries. The lab explores the role of specific proteins in neurotoxicity and cognitive impairment, as well as using advanced imaging techniques to monitor brain function in newborns with hypoxic-ischemic encephalopathy. Through their research, the lab aims to develop new therapeutic strategies to mitigate these serious health issues.

Dr. Barbara Stauch Slusher's lab at Johns Hopkins University focuses on innovative ways to combat age-related muscle loss, known as sarcopenia. The research specifically investigates a targeted delivery system using dendrimers, which are nanoparticles that can deliver drugs effectively to the right cells, such as activated macrophages in aging muscles. By optimizing a potential treatment that inhibits a specific enzyme involved in muscle degradation, the lab aims to improve muscle function and quality of life for older adults.

Dr. Hussein N. Yassine's lab focuses on understanding the links between type II diabetes, Alzheimer's disease, and cognitive decline, particularly within Latino communities at higher risk for these conditions. The lab works on both understanding brain health through imaging and developing new drugs aimed at reducing neuroinflammation associated with Alzheimer's. By studying brain mechanics and pharmaceutical interventions, the team aims to identify effective strategies to mitigate cognitive decline in vulnerable populations.

Dr. Graham Ellis-Davies' lab focuses on developing innovative optical technologies that allow for precise control over neuronal function, both in laboratory settings and living organisms. By creating advanced photochemical tools, the lab enables researchers to manipulate neurotransmitter activity and neuron signaling processes, unveiling new insights into cellular physiology. The work is grounded in collaboration with physiologists, ensuring that the technologies meet real biological challenges.

Dr. Audrey D. Lafrenaye's lab at Virginia Commonwealth University focuses on understanding how brain injury affects neuroinflammatory responses, specifically through the actions of microglia, the brain's immune cells. The lab uses higher-order mammals, like micro pigs, to study microglial behaviors and their potential effects on brain recovery. This research aims to improve our understanding of traumatic brain injury and guide the development of effective treatments for patients suffering from such injuries.

Dr. Argye E. Hillis's lab focuses on understanding how language deficits caused by stroke can improve over time. They study different recovery mechanisms, including the restoration of blood flow to affected brain areas and the reorganization of brain networks. The lab aims to identify factors that can predict individual recovery patterns, helping to develop personalized treatments for people with aphasia.

Dr. Maarten G Lansberg's lab at Stanford University focuses on improving prevention strategies for stroke recurrence. They are conducting the CLARITY trial, which aims to evaluate whether adding cilostazol to standard treatment can significantly lower the risk of further strokes and cardiovascular events in a diverse population. This research is vital as it seeks to address the underutilization of cilostazol in the United States, potentially benefiting millions of stroke survivors with a safe and affordable treatment option.

Dr. Emily Larsen Dennis's research lab focuses on improving the understanding and treatment of traumatic brain injuries (TBI) in children and adolescents. They are developing a comprehensive toolbox that addresses current limitations in neuroimaging analysis for pediatric populations, specifically tailored to the unique challenges presented by younger patients. This innovative approach aims to establish personalized profiles of pathology to better identify factors related to recovery and long-term outcomes for TBI patients.

Dr. Brigitte Lavoie's research focuses on understanding gallbladder diseases, particularly how inflammation and muscle dysfunction in the gallbladder contribute to the formation of gallstones. By investigating the cellular mechanisms that affect gallbladder contraction and researching potential treatments, her lab aims to provide insights that could lead to better management of this common digestive disorder.

Amy Lee's lab at the University of Texas at Austin focuses on understanding how specific proteins, like caldendrin, influence touch sensation and behavioral responses in the context of neurodevelopmental disorders such as autism. The research investigates the molecular mechanisms behind touch sensitivity and its implications for cognition and social behavior, particularly examining differences between male and female responses. The goal is to uncover pathways that may lead to better diagnostics and interventions for these disorders.